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NRP1 (neuropilin-1) is a transmembrane glycoprotein that is required for embryonic neuronal and vascular devel-
opment.1,2 In endothelial cells, NRP1 acts as a coreceptor for 
VEGF (vascular endothelial growth factor)-A, forming het-
erocomplexes with the VEGFR2 (VEGF receptor tyrosine 
kinase), which mediate optimal VEGF signaling and endo-
thelial cell migration essential for angiogenesis.3–5 NRP1 also 
mediates endothelial signaling pathways essential for endo-
thelial cell motility, including tyrosine phosphorylation of 
p130Cas and paxillin, and activation of small GTPases.6–11
See cover image
Alternative splicing of mRNA encoding NRP1 gives rise 
to several sNRP1 (soluble NRP1) isoforms containing the a1/
a2 and b1/b2 domains but lacking the MAM (c), transmem-
brane, and cytoplasmic domains.3,12 These species encode iso-
forms varying from 551 to 704 amino acid residues in size, 
at least 2 of which, s12NRP1 (NRP1 isoform b) and sIVNRP1 
(NRP1 isoform c), are expressed in protein form. sNRP1s 
may act as decoys, competitively binding and sequestering 
VEGF165, thereby mimicking the effect of VEGF165 withdrawal 
and negatively regulating angiogenesis in, for example, tumor 
cell growth.13 It has also been proposed that binding of sNRP1 
dimers to VEGF165 could mediate VEGF delivery to endothe-
lial cell VEGFR2, thereby promoting angiogenesis.14 Another, 
less well-studied, mechanism for generation of NRP1 protein 
isoforms is posttranslational proteolytic cleavage of the full-
length protein. Production of an sNRP1 species was reported 
to be induced by the Ca2+ ionophore, ionomycin, in COS-7 
and mouse embryo fibroblasts via ADAM (a disintegrin and 
metalloproteinase)10-dependent pathway.15 Furthermore, 
NRP1 exodomain shedding in axons via ADAM10 and 
ADAM17 has been shown to play an important physiological 
role in mediating axonal desensitization to Sema3A essential 
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dependent manner. Transduction of endothelial cells with adenoviral constructs expressing NRP1 C-terminal domain fragments 
inhibited VEGF-induced phosphorylation of VEGFR2 (VEGF receptor tyrosine kinase)/KDR (kinase domain insert receptor) 
and decreased VEGF-stimulated endothelial cell motility and angiogenesis in coculture and aortic ring sprouting assays.
Conclusions—These findings identify novel NRP1 species in endothelial cells and demonstrate that regulation of NRP1 
proteolysis via ADAMs 9 and 10 is a new regulatory pathway able to modulate VEGF angiogenic signaling.
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for embryonic neuronal homing.16 However, the relevance 
of ADAM-dependent NRP1 cleavage in endothelial cells is 
unclear. Furthermore, neither the nature nor the function of 
NRP1 species generated by cleavage is known.
Herein, we report the expression in endothelial cells of novel 
NRP1 protein species containing the cytoplasmic domain, but 
lacking the regions of the extracellular domain essential for 
binding of VEGF and semaphorin ligands. We demonstrate that 
expression of NRP1 cytoplasmic domain species in endothelial 
cells is mediated through ADAM-dependent cleavage and is 
stimulated by VEGF. Overexpressing NRP1 species containing 
the cytoplasmic domain inhibited VEGF stimulation of recep-
tor signaling, cell migration, and angiogenesis. These findings 
identify a novel mechanism in endothelial cells that may poten-
tially regulate the VEGF/NRP1 signaling network, with impli-
cations for understanding the control of angiogenesis.
Materials and Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Cells
Human umbilical vein endothelial cells (HUVECs) were purchased 
from TCS CellWorks (Bucks, United Kingdom) and cultured in endo-
thelial basal medium (Cambrex BioScience Ltd, Nottingham, United 
Kingdom) supplemented with gentamicin-ampicillin, epidermal 
growth factor, bovine brain extract (Singlequots; Cambrex), and 10% 
fetal bovine serum (Life Technologies, Paisley, United Kingdom). 
HUVECs used in experiments were no more than passage 6. Human 
coronary artery smooth muscle cells were purchased from PromoCell 
(Heidelberg, Germany).
Antibodies, Drugs, and Small Interfering RNAs
Antibodies to the NRP1 carboxy terminus (C-19; sc-7239), glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH; V-18, sc-20357), 
ADAM9 (sc-23290), ADAM17 (TACE; C15, sc-6416), and 
VEGFR2/KDR (kinase domain insert receptor; A-3, sc-6251) were 
from Santa Cruz Inc (Santa Cruz, CA). NRP1 extracellular domain 
antibody (catalog no. AF3870) was from R&D Systems (Abingdon, 
United Kingdom). Phospho-VEGFR2 (Y1175, number 2478) and 
Notch intracellular cleavage domain (number 4147) antibodies were 
from Cell Signaling Technology Inc (Danvers, MA). Antibody to 
ADAM10 was from Sigma Aldrich (catalog no. A2726). Predesigned 
small interfering RNAs (siRNAs) targeted against ADAMs 9, 10, 17 
(Table) or scrambled control were purchased from GE Healthcare 
(Little Chalfont, United Kingdom) and used for transfection as pre-
viously described.7 PMA, GI254023X, marimastat, chloroquine, 
and lactacystin were purchased from Sigma Aldrich (Dorset, United 
Kingdom); Ionomycin was purchased from Merck Millipore (Herts, 
United Kingdom).
Adenovirus Generation
All reagents used for the generation of adenovirus constructs were 
from Thermo Fisher Scientific. Adenoviruses (Ad) expressing human 
wild-type NRP1 (Ad.NRP1 WT), NRP1 lacking the intracellular 
domain (Ad.NRP1ΔC), NRP1 containing only the cytoplasmic and 
transmembrane domains (Ad.NRP1Cyt-TM), NRP1 containing the 
cytoplasmic, transmembrane, and juxtamembrane domains (Ad.
NRP1Cyt-JM), and NRP1 containing the cytoplasmic, transmem-
brane, juxtamembrane, and MAM domains (Ad.NRP1Cyt-MAM) 
were generated using the Gateway system. Briefly, NRP1 open read-
ing frames were subcloned into the pENTR/D-TOPO vector by PCR 
amplification with primers designed according to the manufacturer’s 
instructions (listed below) and using directional TOPO cloning. 
NRP1 adenoviral expression vectors (pAd/CMV/V5-DEST) were 
generated by recombination, and adenovirus was produced by trans-
fection into host human embryonic kidney 293A cells. Viral particles 
were released from the human embryonic kidney 293A cells by 3 
freeze-thaw cycles and purified using the Adenopure adenovirus puri-
fication kit (Puresyn, Inc), the virus titers were then determined using 
QuickTiterTM Adenovirus Titer quantification kit (Cell Biolabs, 
Inc), and purified adenoviruses were stored at −80°C. HUVECs were 
infected with one of the Ads described above or Ad.LacZ at a mul-
tiplicity of infection of 100. The primers used for the generation of 
Ad.NRP1WT, Ad.NRP1ΔC, Ad.NRP1Cyt-TM, Ad.NRP1Cyt-JM, 
and Ad.NRP1Cyt-MAM were as follows:
Ad.NRP1ΔC:
Forward: 5′-GCTGTCTGTGGGGTCGTGCTGTAGTGTGCC 
TGTTGGCATAATGG-3′ and,
Reverse: 5′-CCATTATGCCAACAGGCACACTACAGCAC 
GACCCCACAGACAGC-3′
Ad.NRP1WT: Forward: 5′-CACCATGGAGAGGGGGCTG 
CC-3′,
Ad.NRP1Cyt-TM: Forward: 5′-CACCATGATCCTCATCACCAT 
CATAGCC-3′,
Ad.NRP1Cyt-JM: Forward: 5′-CACCATGGACATTAGTATTAA 
TAACCACATTTCACAA-3′,
Ad.NRP1Cyt-MAM: Forward: 5′-CACCATGACCATACAATCA 
GAGTTTCCAACA-3′
The reverse primer for the WT, Cyt-TM, Cyt-JM, and Cyt-
MAM constructs is: Reverse: 5′-TCATGCCTCCGAATAAGTA 
CTCTGTG-3′.
Western Blotting
Cytoplasmic and nuclear extracts were obtained using a ProteoJet 
Cytoplasmic and Nuclear Protein extraction kit (Fermentas Life 
Sciences, United Kingdom) according to the manufacturer’s 
instructions. For immunoblotting, cells and cell extracts were pre-
pared by addition of a solution containing 50 mmol/L Tris-HCl 
(pH 7.5), 1% Triton X-100, 150 mmol/L NaCl, 5 mmol/L EDTA, 
complete protease inhibitor (Roche; Sussex, United Kingdom), 
and phosphatase inhibitors I and II (Sigma) and analyzed by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 
4% to 12% Bis-Tris gels (NuPAGE; Life Technologies), fol-
lowed by electrotransfer on to Invitrolon polyvinylidene difluo-
ride membranes (Life Technologies). Membranes were blocked 
with 5% (wt/vol) nonfat dry milk and 0.1% (vol/vol) Tween 20 in 
phosphate-buffered saline for 1 hour at room temperature before 
being probed with the primary antibody by overnight incubation 
at 4°C, followed by incubation for 1 hour at room temperature 
with a horseradish peroxidase-linked secondary antibody (Santa 
Cruz) and detection using ECL plus reagents (GE Healthcare) in 
accordance with the manufacturer’s protocol. For immunoblot-
ting of shed NRP1 ectodomain, supernatants from treated cells 
were pooled together and concentrated using Amicon centrifugal 
filtration devices with a 10 kDa cut off according to the manufac-
turer’s instructions, and samples were then prepared for immu-
noblotting as described above. All immunoblots were quantified 
by scanning films with a calibration strip and analyzed by den-
sitometry using ImageJ (US National Institutes of Health; http://
rsb.info.nih.gov/ij/).
Nonstandard Abbreviations and Acronyms
Ad adenoviruses
ADAM a disintegrin and metalloproteinase
HUVEC human umbilical vein endothelial cells
NRP1 neuropilin-1
siRNA small interfering RNA
sNRP1 soluble NRP1
TNF tumor necrosis factor
VEGF vascular endothelial growth factor
VEGFR2 VEGF receptor tyrosine kinase
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Co-Immunoprecipitation
HUVECs cultured in 10 cm dishes were infected with the differ-
ent adenoviral constructs. Forty-eight hours postinfection, the cells 
were incubated in medium containing 0.5% fetal bovine serum for 
16 hours. Next morning, cells were stimulated with 25 ng/mL VEGF 
for 10 minutes. The cells were then lysed using an IP buffer (PBS 
containing 0.1% NP-40 with protease inhibitor cocktail). The lysates 
were immunoprecipitated with an antibody to VEGFR2 (Santa Cruz; 
sc-6251) using the Dynabeads Protein G Kit (Life Technologies), as 
per the manufacturer’s instructions. The immunoprecipitated pro-
teins were separated on a 4% to 12% SDS-PAGE gel, transferred to a 
PVDF membrane and probed with antibodies.
Sequencing
HUVECs cultured in 15 dishes (15 cm each, VWR International, 
Leicestershire United Kingdom) were infected with Ad.NRP1. After 
48 hours of infection, they were stimulated with Phorbol ester for 24 
hours to stimulate the generation of cytoplasmic fragments. Protein 
lysates were prepared in IP buffer (PBS containing 1% NP-40) and 
immunoprecipitated with the C-19 antibody using Dynabeads G, as 
per the manufacturer’s instructions. The immunoprecipitated com-
plex was resolved on a 4% to 12% SDS-PAGE gel, transferred as 
described above and the PVDF membrane was stained with Ponceau 
S (Sigma). All positively stained bands <25 kDa were sent for 
automated N-terminal sequencing by Edman degradation to Alta 
Biosciences, University of Birmingham.
Cell Migration Assay
Transwell cell culture inserts (BD Biosciences, Oxford, United 
Kingdom) were inserted into a 24-well plate. Serum-free medium with 
or without the indicated growth factors or the vehicle was placed in the 
bottom chamber, and cells in suspension (1.5×105 per well in serum-
free endothelial basal medium were added to the top chamber and 
incubated at 37°C for 4 hours. Cells that had not migrated or had only 
adhered to the upper side of the membrane were removed before the 
membrane was fixed and stained with a Reastain Quik-Diff kit (IBG 
Immucor Ltd, West Sussex, United Kingdom) using the manufactur-
er’s protocol and mounted on a glass slide. Cells that had migrated to 
the lower side of the membrane were counted at ×8 magnification.
Aortic Ring Assay of Angiogenic Sprouting
The murine aortic ring angiogenesis assay was set up as described 
previously.9 In some experiments, aortic rings were infected with 
adenoviral constructs overnight in Opti-MEM (Life Technologies) on 
the day of harvest. Medium containing either no addition (control) or 
supplemented with 30 ng/mL VEGF, was replaced and fresh growth 
factors supplemented every 2 to 3 days. After 1 week, the aortic rings 
were fixed with 4% formalin for 30 minutes at room temperature. 
The fixed rings were permeabilized with PBS containing 0.25% 
Triton X-100 for 15 minutes (2×), blocked with casein solution for 
30 minutes and incubated overnight with DyLight 594 Labeled GSL 
I-isolectin B4 (Vector Laboratories, 1:100) and anti-NRP1 antibody 
(Abcam, clone EPR3113) at 4°C. Negative controls were either incu-
bated with PBS (for the isolectin B4-DyLight 594 antibody conjugate 
control) or rabbit IgG (for the Nrp1 antibody control) instead of pri-
mary antibody. Next morning, rings were washed 3× with PBS, and 
incubated for 1 hour in the dark with Alexa Fluor 488-conjugated 
donkey anti-rabbit IgG (Life Technologies), mounted on slides and 
imaged under a fluorescent microscope (Zeiss Axio Imager A1). The 
isolectin stained images were analyzed using Image J to evaluate the 
total area of outgrowth and number of branch points by an observer 
blinded to the treatments given.
Immunofluorescent Staining
HUVECs were plated onto glass coverslips precoated with attach-
ment factor (Life Technologies). The following day cells were 
infected with the adenoviral constructs and after an overnight incuba-
tion, the medium was replaced with fresh endothelial basal medium 
containing 10% fetal bovine serum. Forty-eight hours after infection, 
cells were rinsed 3× with PBS and fixed in 4% paraformaldehyde for 
10 minutes followed by permeabilization with 0.1% Triton X-100 in 
PBS for 10 minutes. Cells were blocked in 1% BSA for 30 minutes at 
room temperature and incubated overnight at 4°C with C-19 antibody 
in PBS containing 1% BSA, or normal goat IgG for the negative con-
trol. After washing with PBS, cells were then incubated for 1 hour in 
the dark with Alexa Fluor 488-conjugated donkey anti-goat IgG (Life 
Technologies). Cells were then rinsed 3× with PBS then mounted 
using ProLong Gold antifade reagent with DAPI (Life Technologies). 
Images were acquired using a Leica TCS SP2 confocal microscope 
using a Planapo 63×/1.25 oil immersion objective and images were 
acquired in the horizontal (x-y) and in the vertical (x-z) planes by 
the LAS-AF software. Offline analysis was performed using ImageJ.
VEGFR2 Phosphorylation
VEGFR2 phosphorylation was determined as described previously.7
Statistical Analysis
Values have been presented as scatterplots with individual data 
points. Data were tested for normality using the Shapiro-Wilk test 
and equality of variance using the Levene test. Where necessary data 
were log transformed before being analyzed using either 1-way or 
2-way ANOVA as appropriate with the Bonferroni correction for 
multiple pairwise comparisons.
Results
Expression of NRP1 Fragments Containing the  
Cytoplasmic Domain
Western blots of lysates of HUVECs with an antibody spe-
cific for the cytoplasmic domain of NRP1 detected the major 
full-length NRP1 protein of 130 kDa, but additionally recog-
nized several smaller species with molecular weights of ≈10, 
15, 25, and 30 kDa, primarily in the cytoplasmic compartment 
with less expression detected in nuclear extracts (Figure 1A). 
An antibody directed against the extracellular NRP1 region 
did not recognize these low molecular weight NRP1 species 
(results not shown). Immunoblots of human coronary artery 
smooth muscle cells and of breast cancer MB231 cells also 
detected several small NRP1 species recognized by antibod-
ies specific for the cytoplasmic domain in addition to the 
130 kDa full-length protein (Figure I in the online-only Data 
Supplement and results not shown). To examine the specificity 
of the NRP1 immunoreactivity of these species, NRP1 knock-
down was performed using NRP1-targeted siRNA. As shown 
in Figure 1B, NRP1-specific siRNA depleted both the 130 
kDa NRP1 protein and the low molecular weight C-terminal 
Table. ADAM siRNAs Used in This Study
siRNA Target Sequence
ADAM9.1 GAGUUAACUAGAGAAAGA 
ADAM9.2 GGAGGGAGUUCAUAAUUCA
ADAM9.3 GUGCACAGCUAGUUCUAAA
ADAM10 GAACUAUGGGUCUCAUGUA
ADAM17.1 GAAGAACACGUGUAAAUUA
ADAM17.2 GGAAAUAUGUCAUGUAUCC
ADAM17.3 GCACAAAGAAUUAUGGUAA
ADAM indicates a disintegrin and metalloproteinase; and siRNA, small 
interfering RNA.
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domain species. Furthermore, transduction of HUVECs with 
an adenoviral construct encoding full-length wild-type NRP1 
resulted in increased expression of both a major 130 kDa band 
corresponding to full-length NRP1, and of 2 lower molecular 
weight bands, of 10, and 15 kDa, very similar in size to endog-
enous bands detected in HUVECs that were recognized by 
cytoplasmic domain antibody, but not by antibody directed to 
the extracellular NRP1 domain (Figure 1C). In contrast, ade-
noviral expression of a NRP1 mutant lacking the cytoplasmic 
domain (Ad.NRP1∆C), gave rise to increased expression of a 
major band of ≈120 kDa that was recognized by antibodies to 
the extracellular NRP1 domains and corresponds to the pre-
dicted molecular weight of the NRP1∆C protein, but did not 
result in expression of smaller species that could be detected by 
antibody specific for the cytoplasmic domain (Figure 1C). A 
band of ≈30 kDa was also detected by antibody specific for the 
NRP1 cytoplasmic domain in cells overexpressing wild-type 
NRP1 but not in cells overexpressing NRP1∆C (Figure 1C).
Cytoplasmic Domain NRP1 Fragments Are 
Generated via Proteolytic Cleavage by ADAMs  
9 and 10
To test the possibility that expression of small C-terminal 
NRP1 fragments could result from proteasomal or lyso-
somal degradative pathways, we examined whether inhibi-
tors of endocytotic trafficking and lysosomal or proteasomal 
degradation had any effect on expression of NRP1 cyto-
plasmic domain species.17 Treatment with the proteasomal 
inhibitor, lactacystin, caused no decrease in the level of NRP1 
C-terminal fragments, but instead resulted in a marked increase 
in expression of the 10 and 15 kDa C-terminal NRP1 bands, 
which was concentration-dependent, a detectable increase in 
C-terminal domain species being observed at 1 µmol/L, and 
a greater increase at 3 and 10 µmol/L lactacystin (Figure IIA 
in the online-only Data Supplement). Treatment of HUVECs 
with chloroquine, which blocks endosomal acidification and 
membrane trafficking of VEGFR2 in endothelial cells,17 also 
resulted in a marked increase in the level of C-terminal NRP1 
species (Figure IIB in the online-only Data Supplement). 
These findings indicate that NRP1 C-terminal domain species 
undergo endocytosis and degradation via both proteasomal 
and lysosomal pathways, but are not themselves the products 
of these degradative pathways.
It was next investigated whether expression of C-terminal 
NRP1 fragments could result from posttranslational proteo-
lytic cleavage mediated by a membrane-bound or extracellular 
proteinase, such as a matrix metalloproteinase or γ-secretase. 
Treatment with the γ-secretase inhibitor, DAPT, had no sig-
nificant effect on expression of C-terminal NRP1 species, but 
markedly inhibited constitutive expression of the Notch cyto-
plasmic domain, which is produced specifically via γ-secretase 
cleavage (Figure IIC in the online-only Data Supplement). In 
A B C
Figure 1. Endothelial expression of C-terminal NRP1 (neuropilin-1) fragments. A, Lysates of cytoplasmic (Cyt, C) and nuclear extracts 
(Nuc, N) of human umbilical vein endothelial cells (HUVECs) were immunoblotted with NRP1 antibody specific to the cytoplasmic domain 
of NRP1 (C-term; antibody C-19 from Santa Cruz Inc). This antibody recognized several low (30 kDa and below) molecular weight species 
predominantly in the cytoplasmic fraction. B, HUVECs were transfected with control scrambled (siScr) and NRP1-specific siRNAs, and 
whole cell protein lysates immunoblotted with NRP1 antibody specific either to the cytoplasmic (C-term) or extracellular (N-term; antibody 
AF387) domains of NRP1. Knockdown of endogenous NRP1 using siRNA resulted in diminished expression of not only the full-length 
NRP1 band but also of the cytoplasmic fragments. C, HUVECs were transduced with adenoviruses encoding wild-type (WT) NRP1 (WT), 
an NRP1ΔC mutant lacking the cytoplasmic domain (ΔC), or GFP (green fluorescent protein), and 48 h later cytoplasmic (C) or nuclear (N) 
cell lysates were immunoblotted with antibodies either specific for the NRP1 cytoplasmic domain (C-term), or specific to the NRP1 extra-
cellular domain (N-term), or for β-actin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH; cytoplasmic marker), or lamin B (nuclear 
marker). Overexpression of WT NRP1 by an adenovirus (WT), but not of the NRP1ΔC mutant (lacking the cytoplasmic domain; ΔC) results 
in the generation of low molecular weight cytoplasmic fragments that can be detected only by antibody specific for the NRP1 cytoplasmic 
domain, but not by antibody specific for the NRP1 extracellular domain.
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contrast, treatment of HUVECs with a broad-specificity inhib-
itor of metalloproteinases, marimastat, significantly reduced 
expression of the 10 and 15 kDa NRP1 fragments (Figure 2A). 
This effect was concentration-dependent with a half-max-
imum effect (IC50) of ≈10 μmol/L marimastat (Figure 2B), 
similar to the reported concentration-dependent effects of 
this compound in intact cells.15 Metalloproteinase-mediated 
ectodomain shedding of membrane-associated molecules is 
stimulated by phorbol esters and calcium ionophores, which 
respectively activate PKCs (protein kinase C) and increase 
intracellular Ca2+.18,19 Because generation of NRP1 C-terminal 
domain species might be a consequence of NRP1 extracellular 
domain shedding, we therefore examined the effects of PMA 
and the ionophore ionomycin on expression of these protein 
species. As shown in Figure 2C, PMA caused a concentra-
tion-dependent increase in the level of the NRP1 10 and 15 
kDa C-terminal fragments. Ionomycin also strongly increased 
expression of the 10 and 15 kDa NRP1 C-terminal fragments 
at 1 μmol/L, an effect which diminished at higher concentra-
tions of ionomycin (Figure 2C), because of a large increase in 
cell detachment and loss of endothelial cell viability observed 
on incubation for 24 hours at concentrations >1 μmol/L.
These findings suggested that NRP1 cytoplasmic domain 
fragments could be generated from full-length NRP1 by pro-
teolytic cleavage mediated via an extracellular or membrane-
associated protease, such as a member of the ADAM family. 
ADAMs family members that are expressed and shown to have 
functional roles in endothelial cells include ADAMs 9, 10, 
15, and 17,16,20,21 and we therefore focused on these ADAMs. 
Knockdown of ADAM9 or ADAM10 using specific siRNAs 
caused a marked and significant reduction in the endogenous 
level of NRP1 C-terminal fragments (Figure 3A and 3B). In 
contrast, targeted depletion of ADAM17 had little effect on 
expression of either full-length NRP1 or NRP1 C-terminal 
A
C
B
Figure 2. The generation of NRP1 (neuropilin-1) cytoplasmic fragments in human umbilical vein endothelial cells (HUVECs) is mediated by 
metalloproteinase activity. A, Increasing concentrations of marimastat, a broad-spectrum metalloproteinase inhibitor, reduces the expres-
sion of the 10 and 15 kDa fragments detected by antibody specific for the NRP1 cytoplasmic domain (C-term) in a dose-dependent man-
ner. B, The dose-response curve for the effect of marimastat on generation of the 10 kDa NRP1 cytoplasmic fragment indicates an IC50 of 
10 μmol\L, similar to reported values for marimastat. C, HUVECs, either infected with Ad.NRP1WT or uninfected (UI) were treated for 24 
h with Phorbol ester (PMA), or Ionomycin (IM), or vehicle (DMSO) control (VC), at the indicated concentrations, and cell lysates were then 
prepared and immunoblotted as shown.
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A
D
E
B C
Figure 3. NRP1 (neuropilin-1) cleavage in endothelial cells is mediated by ADAMs (a disintegrin and metalloproteinases) 9 and 10. Human 
umbilical vein endothelial cells (HUVECs) were transfected with control siRNA (siScr) or siRNAs specific for ADAM9 (A) or ADAM10 (B), 
and after 72 h were then treated with 25 ng/mL VEGF (vascular endothelial growth factor) for 60 min; cell lysates were then immunoblot-
ted with the antibodies indicated. C, HUVECs were treated for 24 h with either no additions, or with DMSO (vehicle), or with the indicated 
concentrations of GI254023X, a specific inhibitor of ADAM10, and cell lysates were then immunoblotted with the antibodies indicated; 
quantification of the 10 kDa NRP1 cytoplasmic domain band is shown, *P<0.05 vs DMSO treatment, n≥3. D, Effects of single and double 
knockdown of ADAM9 and ADAM10 on the expression of NRP1 cytoplasmic domain fragments. The blots shown are representative of 4 
different experiments. E, Quantification of the 10 kDa NRP1 cytoplasmic fragment from experiments in D, normalized to glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) expression, after knockdown of ADAMs 9 or 10 using single siRNAs at 200 nmol/L (black sym-
bols), or double knockdown of ADAM9 plus ADAM10 (unfilled symbols) using combinations of siRNAs (total siRNA concentration 400 
nmol/L); *P<0.05 vs Scr siRNA (200 nm) or Scr siRNA (400 nm) as appropriate. Values are presented as a scatterplot. Differences between 
samples were analyzed using 1-way ANOVA with the Bonferroni correction for multiple pairwise comparisons after testing for normality 
and equal variance using the Shapiro-Wilk and Levene tests, respectively.
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species (Figure III in the online-only Data Supplement). 
Knockdown of ADAM15 also caused no significant reduction 
in expression of NRP1 C-terminal species (data not shown). 
To further validate the conclusion that NRP1 C-terminal 
domain fragments were generated via an ADAM-dependent 
pathway, we also examined the effect of the specific ADAM10 
inhibitor, GI254023X.22 Treatment of endothelial cells with 
GI254023X markedly reduced endogenous generation of 10 
and 15 kDa NRP1 C-terminal bands (Figure 3C). The effect 
of GI254023X was concentration-dependent with a decrease 
in expression of the 10 and 15 kDa NRP1 C-terminal bands 
detectable at 3 μmol/L and a more striking reduction observed 
at 10 μmol/L. We also examined the effects of double knock-
down of ADAMs 9 and 10. As indicated in Figures 3D and 
3E, targeted depletion of both ADAMs caused a more marked 
decrease in the level of 10 and 15 kDa NRP1 C-terminal bands 
compared with the effects of single knockdowns.
VEGF Regulation of Cytoplasmic domain 
NRP1 fragments via ADAMs 9 and 10
Our findings supported the conclusion that generation of 
NRP1 C-terminal domain fragments was the consequence 
of a constitutive proteolytic process mediated via ADAMs 9 
and 10. To investigate whether formation of these fragments 
was regulated by physiological stimuli, we tested the effects 
of VEGF on generation of NRP1 C-terminal domain species. 
As shown in Figure 4A, VEGF increased formation of the 10 
kDa NRP1 C-term species, with a consistent and significant 
increase in expression of 10 and 15 kDa NRP1 C-terminal 
bands after 1-hour treatment with VEGF. Furthermore, knock-
down of either ADAM9 or ADAM10 blocked the VEGF-
induced increase in generation of these C-terminal domain 
fragments (Figure 4B). VEGF treatment also caused a marked 
and significant increase in generation of a soluble extracellu-
lar fragment of NRP1 (sNRP1) of ≈120 kDa, consistent with 
previous findings,16 which was detected in endothelial cell 
supernatant using antibody specific for the NRP1 ectodomain 
(Figure 4C; Figure IV in the online-only Data Supplement). 
VEGF-induced NRP1 ectodomain shedding was also inhib-
ited by knockdown of ADAM10 and by ADAM10 inhibi-
tion using GI254023X, indicating that ADAM10 cleavage of 
NRP1 resulted in generation of a sNRP1 containing most of 
the extracellular domain comprising the VEGF and Sema3 
ligand-binding regions, and NRP1 species containing the 
cytoplasmic, and possibly other domains including the trans-
membrane and MAM domains. We also examined the pos-
sibility that generation of NRP1 C-terminal domain fragments 
could be regulated by other cytokines. Our studies showed 
that treatment of endothelial cells with TNF (tumor necrosis 
factor)-α for 24 hours also significantly increased expression 
of the major 10 kDa NRP1 C-terminal fragment (Figure V in 
the online-only Data Supplement).
Our data indicated that expression of low molecular 
weight NRP1 C-terminal species was the result of ADAM-
mediated cleavage of full-length membrane-associated NRP1 
giving rise to 2 major NRP1 C-terminal species of ≈10 and 
15 kDa. Based on molecular weight and immunoreactivity, 
these species were predicted to contain the cytoplasmic and 
transmembrane domains plus part of the juxtamembrane and 
MAM extracellular regions. To obtain further insight into the 
cleavage sites utilized by ADAM 9 and 10 giving rise to these 
species, we sought to obtain protein sequence data for these 
C-terminal species in endothelial cells. To obtain sufficient 
protein for sequencing, the expression of NRP1 C-terminal 
cleavage products was increased by adenovirally overexpress-
ing NRP1 in endothelial cells and further stimulating cleav-
age by treatment with PMA (Figure 2C). NRP1 was then 
immunoprecipitated using antibody specific to the C-terminal 
domain, and potential cleavage products were identified by 
Ponceau S staining. It was confirmed that expression of 10 
and 15 kDa NRP1 fragments immunoprecipitated by anti-
body specific to the NRP1 C-terminal domain and detected 
by Ponceau S staining was inhibited by treatment of cells with 
the ADAM10-specific inhibitor, GI254023X (Figure 5A). 
Edman degradation sequencing of Ponceau S stained NRP1 
fragments immunoprecipitated by antibody specific to the 
NRP1 C-terminal domain (Figure 5B) showed that the 10 
and 15 kDa NRP1 bands had N-terminal sequences compris-
ing, respectively, DISI (Asp Iso Ser Iso) juxtamembrane to 
the MAM domain, and TIQSE (Thr Iso Gln Ser Glu) near 
the N-terminal end of the MAM domain (Figure 5C). These 
findings suggest that ADAMs 9 and 10 cleave NRP1 in its 
extracellular region resulting in at least 2 species comprising 
either the cytoplasmic, transmembrane, and juxtamembrane 
domains, or the cytoplasmic, transmembrane, juxtamem-
brane, and MAM domains (Figure 5C, right).
C-Terminal Domain NRP1 Fragments Inhibit 
VEGF Angiogenic Signaling in Endothelial Cells
To investigate whether NRP1 C-terminal domain species gen-
erated by ADAM-dependent cleavage could exert functional 
effects in HUVECs independently of the NRP ligand-binding 
domain, we generated adenoviral (Ad) constructs encod-
ing either NRP1WT (Ad.NRP1), or different NRP1 deletion 
mutants, and compared their effects on VEGF angiogenic sig-
naling in endothelial cells. The constructs tested comprised 
either the cytoplasmic and transmembrane domains (Ad.
NRP1Cyt-TM, residues 860–923), the cytoplasmic, trans-
membrane, and juxtamembrane regions (Ad.NRP1Cyt-JM, 
residues 797–923), or the cytoplasmic, transmembrane, jux-
tamembrane, and MAM domains (Ad.NRP1Cyt-MAM, resi-
dues 638–923; Figure 6A). Expression of all constructs in 
HUVECs was confirmed by Western blot (data not shown) and 
by immunofluorescent staining (Figure VI in the online-only 
Data Supplement). NRP1 is strongly implicated in mediating 
VEGF stimulation of endothelial cell migration.3–5,7,8Therefore, 
initially we determined effects of NRP1 cytoplasmic domain-
containing constructs in assays of VEGF-stimulated endo-
thelial cell chemotactic migration. As shown in Figure 6B, 
in endothelial cells expressing Ad.NRP1WT or Ad.LacZ, 
VEGF induced a striking chemotactic response, whereas cells 
expressing either Ad.NRP1Cyt-TM, Ad.NRP1Cyt-JM, or 
Ad.NRP1Cyt-MAM exhibited a significantly reduced migra-
tory response to VEGF compared with cells expressing either 
Ad.NRP1WT or Ad.LacZ. In contrast, none of the adenovi-
ruses expressing either WT NRP1 or truncated C-terminal 
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Figure 4. ADAMs (a disintegrin and metalloproteinases) 9 and 10 mediate VEGF (vascular endothelial growth factor)-induced NRP1 (neuro-
pilin-1) proteolytic cleavage. A, Human umbilical vein endothelial cells (HUVECs) were transfected with siRNAs as indicated, and after 72 h 
were then treated with 25 ng/mL VEGF-A for 60 min, and lysates were then immunoblotted as indicated. B, Quantification of the 10 kDa NRP1 
cytoplasmic domain fragment in experiments in A in which HUVECs were treated without (C, unfilled symbols) or with VEGF-A (V, black sym-
bols); VEGF significantly enhanced the generation of NRP1 cytoplasmic fragments in siScr-treated cells and this was blocked by siADAM9 
(left graph) or siADAM10 (right graph); #P<0,05 vs siScr C, *P<0.05; **P<0.01; ***P<0.005 vs siScr plus VEGF (V; n≥3). C, HUVECs were either 
transfected with control (siScr) and ADAM10 specific siRNAs and were then either untreated (C, control, unfilled symbols)) or treated with 25 
ng/mL VEGF (V, black symbols) for 60 min. Cell supernatant was then removed, concentrated, and immunoblotted NRP1 antibody specific for 
the extracellular domain with (AF3870) to detect sNRP1 (soluble NRP1). Quantification of results from 3 independent experiments is shown 
below; **P<0.01 for siADAM10 vs siScr. D, HUVECs were untreated (C, control, unfilled symbols), or were treated for 60 min with 25 ng/mL 
VEGF plus either DMSO (V, black symbols) or with 25 ng/mL VEGF plus an equal volume of GI254023X (V+G, black symbols). Quantification 
of results from 3 independent experiments is shown below; *P<0.05 for VEGF plus GI254023X (10 μmol/L) vs VEGF plus DMSO. In this figure, 
values are presented as a scatterplot. Differences between samples were analyzed using 1-way ANOVA with the Bonferroni correction for 
multiple pairwise comparisons after testing for normality and equal variance using the Shapiro-Wilk and Levene tests, respectively.
D
ow
nloaded from
 http://ahajournals.org by on September 6, 2018
Mehta et al  ADAM-Mediated NRP1 Cleavage  1853
NRP1 fragments had any effect on endothelial cell prolifera-
tion either with or without addition of VEGF, as determined 
by real-time measurement of cell confluence >72 hours (data 
not shown). This is in agreement with previous findings show-
ing that NRP1 is not required for endothelial cell prolifera-
tion.23 The effects of overexpressing NRP1 C-terminal domain 
species were next examined in an aortic ring assay of sprout-
ing angiogenesis. VEGF induced new angiogenic sprouts in 
aortic rings transduced with either Ad.NRP1WT or Ad.LacZ, 
as determined by endothelial-specific staining and measure-
ment of both branch points and total endothelial network area 
(Figure 6C). NRP1 expression in the endothelial cells of newly 
sprouted vessels was confirmed in aortic rings by co-immuno-
fluorescent staining with the endothelial cell-specific marker 
isolectin B4 (Figure VII in the online-only Data Supplement). 
In contrast, VEGF-induced angiogenesis was markedly 
reduced in aortic rings expressing either Ad.NRP1CytTM, 
Ad.NRP1CytJM, or Ad.NRP1CytMAM as compared with 
control aortic rings expressing Ad.NRP1WT or Ad.LacZ. 
We further examined the effect of NRP1 C-terminal domain 
constructs on angiogenesis in the coculture model of angio-
genesis. Similar to results obtained in the aortic ring assay, 
overexpression of either Ad.NRP1CytTM, Ad.NRP1CytJM, 
or Ad.NRP1CytMAM, reduced endothelial network forma-
tion in the coculture angiogenesis assay in comparison to 
Ad.NRP1WT overexpression (data not shown).
The major angiogenic signaling receptor for VEGF 
in endothelial cells is VEGFR2/KDR. We next exam-
ined whether the inhibitory effects of NRP1 cytoplasmic 
domain constructs on VEGF-induced angiogenesis could be 
explained in part by reduced VEGFR2/KDR activation in 
response to VEGF. As shown in Figure 7A, Ad.NRP1Cyt-TM, 
Ad.NRP1Cyt-JM, or Ad.NRP1Cyt-MAM constructs inhibited 
VEGF-induced VEGFR2/KDR activation, compared with the 
effect of VEGF in cells expressing Ad.NRP1WT or Ad.LacZ. 
VEGF binding to NRP1 and VEGFR2 induces formation of a 
Figure 5. Protein sequencing of NRP1 (neuropilin-1) cleavage products. A, Human umbilical vein endothelial cells (HUVECs) were trans-
duced with Ad.NRP1WT and after 48 h were treated with 30 ng/mL PMA for 24 h in the absence or presence of the ADAM (a disintegrin 
and metalloproteinase) 10 inhibitor, GI254023X (10 μmol/L). Cells were lysed, immunoprecipitated using antibody specific for the NRP1 
cytoplasmic domain (IP: NRP1 C-term; C-19), and proteins were stained with Ponceau S to detect bands. In parallel, HUVECs transduced 
with Ad.NRP1WT for 48 h were lysed and lysates incubated with IgG control. Whole cell lysate of PMA-treated Ad.NRP1WT-infected cells is 
also shown for comparison. B, HUVECs were transduced with Ad.NRP1WT and after 48 h were treated with 30 ng/mL PMA for 24 h. Cells 
were then lysed and full-length NRP1 and the low molecular weight cleavage products were immunoprecipitated using the C-19 antibody 
specific for the NRP1 cytoplasmic domain, and immunoprecipitated proteins separated by SDS-PAGE. Proteins were transferred onto a 
PVDF membrane and stained with Ponceau S to detect bands. The low molecular weight cleavage products, indicated as bands 1 to 4, 
were cut and sent for N-terminal sequencing by Edman degradation. C, Amino acid sequence of NRP1, N-terminal sequences detected 
by N-terminal sequencing by Edman degradation are highlighted in red within the NRP1 sequence. A schematic diagram representing the 
putative sites of NRP1 cleavage by members of the ADAM family, resulting in the generation of cytoplasmic fragments is shown.
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complex between NRP1 and VEGFR2, which is considered 
to play an important role in NRP1-dependent VEGF signal-
ing in the endothelium. We next examined the possibility 
that NRP1 cytoplasmic domain species were able to associ-
ate with VEGFR2 independently of the extracellular ligand-
binding domain, by comparing VEGFR2 association with 
Figure 6. Overexpression of NRP1 (neuropilin-1) cytoplasmic domain fragments in human umbilical vein endothelial cells (HUVECs) 
inhibits VEGF (vascular endothelial growth factor)-induced angiogenesis. A, Schematic diagram representing adenoviral NRP1 constructs 
comprising the cytoplasmic and transmembrane domains (Ad.NRP1Cyt-TM, residues 860–923), the cytoplasmic, transmembrane, and 
juxtamembrane regions (Ad.NRP1Cyt-JM, residues 797–923), and the cytoplasmic, transmembrane, juxtamembrane, and MAM domains 
(Ad.NRP1Cyt-MAM, residues 638–923). B, HUVECs transfected with adenoviruses overexpressing LacZ, wild-type NRP1 (Ad.NRP1WT), 
or the cytoplasmic domain species (Ad.NRP1Cyt-TM, Cyt-JM and Cyt-MAM, respectively) were used in a Transwell migration assay 
with (+, black symbols) and without (−, unfilled symbols) VEGF treatment (25 ng/mL, 4 h); the means±SEM of results from 3 independent 
assays are shown, P<0.05 vs Ad.NRP1WT plus VEGF. C, Aortic rings were incubated with the indicated adenoviruses in Opti-MEM over-
night. The aortic ring assay was performed as detailed in the Materials and Methods with no treatment (−, unfilled symbols) or with VEGF-
A165 treatment (+, black symbols). Quantification of the number of branch points (left graph) and network area (right graph) are shown 
below the representative figures; **P<0.01, ***P<0.001 vs Ad.NRP1 plus VEGF, n=3 (each n includes aortic rings from 4 mice, to have 
sufficient sample to set up each condition using 6 replicate aortic rings). In this figure, values are presented as a scatterplot. Differences 
between samples were analyzed using 2-way ANOVA with the Bonferroni correction for multiple pairwise comparisons after testing for 
normality and equal variance using the Shapiro-Wilk and Levene tests, respectively.
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Figure 7. Overexpression of NRP1 (neuropilin-1) cytoplasmic fragments in human umbilical vein endothelial cells (HUVECs) inhibits KDR 
(kinase domain insert receptor) activation but not VEGF (vascular endothelial growth factor)-induced NRP1 association with KDR. A, 
HUVECs were transfected with adenoviruses overexpressing LacZ, wild-type NRP1 (Ad.NRP1WT), or the low molecular weight species 
(Ad.NRP1Cyt-TM, Cyt-JM, and Cyt-MAM, respectively). After treatment without (−, unfilled symbols) or with VEGF-A165 (+, black symbols) 
for 10 min, cells were lysed and immunoblotted with the indicated antibodies. Quantification of the blots is shown on the right for KDR 
(n=3; *P<0.05 vs Ad.NRP1WT plus VEGF). B, HUVECs overexpressing WT and mutant NRP1s as detailed above were stimulated with 
VEGF for 10 min and KDR was immunoprecipitated. Immunoprecipitates were immunoblotted with an antibody to NRP1. Blots demon-
strating equal KDR immunoprecipitation for each condition are shown on the right-hand side. In this figure, values are presented as a 
scatterplot. Differences between samples were analyzed using 2-way ANOVA with the Bonferroni correction for multiple pairwise com-
parisons after testing for normality and equal variance using the Shapiro-Wilk and Levene tests, respectively.
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NRP1 in cells expressing Ad.NRP1WT, Ad.NRP1Cyt-TM, 
Ad.NRP1Cyt-JM, or Ad.NRP1Cyt-MAM. VEGF treatment 
of HUVECs overexpressing NRP1WT stimulated association 
of VEGFR2/KDR with NRP1 as demonstrated by detection 
of a 130 kDa NRP1 band by Western blotting for NRP1 in 
VEGFR2 immunoprecipitates (Figure 7B). In cells overex-
pressing either NRP1Cyt-TM, NRP1Cyt-JM, or NRP1Cyt-
MAM, Western blot of VEGFR2 immunoprecipitates with an 
NRP1 antibody specific for the C-terminal domain detected a 
10 kDa band corresponding to NRP1Cyt-TM, but at a much 
lower level relative to full-length NRP1 (compare Figure 7B 
with Figure VII in the online-only Data Supplement). 
Furthermore, VEGF treatment caused no change in the degree 
of VEGFR2 co-immunopreciptation with small C-terminal 
domain NRP1 fragments (Figure VIII in the online-only 
Data Supplement). These findings indicate that the NRP1 
C-terminal domain alone, independent of the NRP1 ligand-
binding domain associates with VEGFR2 only weakly and 
that any association is not regulated by VEGF.
Discussion
Here, we report the identification of novel NRP1 protein spe-
cies containing the cytoplasmic domain and the transmem-
brane domain, but lacking the regions of the extracellular 
domain essential for binding of VEGF and semaphorin ligands. 
We show that these species are endogenously expressed in 
human endothelial, vascular smooth muscle, and tumor cells. 
Importantly, we demonstrate that expression of these species 
occurs via a VEGF-regulated and ADAMs-mediated pathway 
resulting in NRP1 ectodomain cleavage and generating novel 
NRP1 species containing the C-terminal domain. We further 
identify proteolytic cleavage of NRP1 by ADAM 9 and 10 
as the major mechanism mediating generation of these NRP1 
fragments. These conclusions are supported by the following 
evidence: (1) siRNAs targeted to either ADAMs 9 and 10 sig-
nificantly reduced endogenous and VEGF-induced expression 
of NRP1 C-terminal 10 and 15 kDa domain species, whereas 
ADAM17 knockdown had no effect; (2) generation of NRP1 
C-terminal 10 and 15 kDa domain species was inhibited by 
the broad-specificity metalloproteinase inhibitor, marimas-
tat, and by the specific pharmacological ADAM10 inhibitor, 
GI254023X; (3) levels of NRP1 C-terminal 10 and 15 kDa 
domain species were increased by PMA and ionomycin, 
known activators of ADAM-like proteolytic activity, whereas 
perturbation of alternative mechanisms, including degrada-
tive pathways and γ-secretase, did not inhibit expression of 
these fragments; and (5) the N-terminal sequences of NRP1 
C-terminal fragments generated by cleavage were similar to 
known consensus sites of ADAMs cleavage.
Protein sequencing of NRP1 C-terminal fragments was 
consistent with cleavage by ADAMs 9 and 10 at 2 sites at the 
juxtamembrane and N-terminal ends of the extracellular MAM 
domain. Furthermore, the sequences at these sites contain the 
motif AVD_DIS characteristic of other predicted ADAMs 
cleavage sites. The consensus sites of ADAMs cleavage are 
relatively poorly characterized,24,25 and there are few unam-
biguously identified sites of ADAM proteolysis. However, the 
protein sequencing of the 2 major C-terminal domain NRP1 
fragments detected in endothelial cells, taken together with 
the fact that ADAM9/10 knockdown and ADAM10 inhibi-
tion strongly inhibited generation of these NRP1 fragments in 
endothelial cells indicates that NRP1 undergoes ADAM9/10-
mediated cleavage at or near these sites (Figure 5). Whether 
ADAM9 and 10 have preference for cleavage at different sites 
is unclear, and knockdown of either ADAMs significantly 
reduced formation of the major 10 kDa C-terminal band. It 
is also unclear whether ADAMs 9 and 10 work processively. 
Unambiguous answers to these questions could not be deter-
mined from ADAM knockdowns.
Ectodomain shedding of cell surface molecules has 
emerged as a major pathway regulating the activity of several 
cell surface molecules with key roles in endothelial cell func-
tion, including VE-cadherin.20,26,27 Ectodomain shedding of 
VEGFR2 by ADAM17,15 or by both ADAM10 and ADAM1722 
was previously reported. Furthermore, Donners et al22 also 
showed that ADAM10 and VEGFR2 can complex with each 
other, that VEGF increases ADAM10 activity, and that phar-
macological inhibition of ADAM10 using GI254023X inhib-
ited VEGF-induced endothelial cell migration. In contrast, 
much less is known about shedding of other endothelial VEGF 
receptors. Shedding of the NRP1 extracellular domain in 
endothelial cells has not previously been described, though 
Swendeman et al15 reported cleavage of the NRP1 ectodo-
main in COS-7 cells in response to ionomycin, and this study 
also implicated ADAM10 in this process by demonstrating 
enhancement of NRP1 shedding by expression of ADAM10, 
but not an inactive ADAM10 mutant, in ADAM10-deficient 
mouse embryo fibroblasts. The findings presented here, iden-
tify NRP1 as a novel substrate for ADAMs 9 and 10 in endo-
thelial cells, and show for the first time that VEGF can regulate 
NRP1 by enhancing ADAM 9 and 10-mediated NRP1 cleav-
age leading to increased generation of NRP1 C-terminal 10 
and 15 kDa domain species. Consistent with this observation, 
VEGF increases ADAM10 activity.22
NRP1 cleavage mediated via ADAM9/10 could play an 
important functional role in regulating the function of NRP1 
in endothelial biology. During mouse and chick embryonic 
development, loss of axonal responsiveness to Sema3A corre-
lates with a sharp decrease in axonal NRP1 expression.16 This 
developmental downregulation of Nrp1 is blocked by genetic 
ablation of ADAM10 and ADAM17, demonstrating an impor-
tant role of ADAM-mediated NRP1 cleavage in physiological 
regulation of axonal guidance cues. NRP1 ectodomain shed-
ding is a potential mechanism through which NRP1-dependent 
VEGF signaling could be downregulated, through the decoy 
role of sNRP1, which might result in a dampening of the 
endothelial chemotactic and angiogenic responses to VEGF. 
Negative feedback regulation of VEGF signaling through 
ADAM-mediated VEGFR and NRP1 ectodomain shedding 
could be important for calibrating VEGF responsiveness to 
achieve a physiologically normal biological effect. Consistent 
with this notion is the finding that pharmacological inhibi-
tion of ADAM10 impairs endothelial cell migration,22 and 
that endothelial-specific ADAM10 knockout in mice results 
in aberrant organ-specific vascularization, including increased 
retinal vascular branching and density. VEGF-induced NRP1 
cleavage via ADAM10 could also potentially regulate NRP1 
function by causing a reduction in the total cellular level of 
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full-length NRP1. However, because VEGF regulation of cel-
lular NRP1 levels can also occur via ligand-induced receptor-
mediated endocytosis,28 and may additionally be influenced 
by other processes such as receptor recycling and de novo 
synthesis, the extent of any contribution of ADAM-mediated 
cleavage to regulation of full-length NRP1 is unclear. Our 
study does not preclude involvement of other ADAMs family 
members in regulating NRP1, a possibility supported by our 
observation that TNF-α also induces NRP1 cleavage. Further 
work will be required to fully elucidate the ADAMs able to 
mediate NRP1 proteolytic cleavage in endothelial cells.
Studies of VEGF receptor processing to date have tended 
to focus either on vesicular trafficking, or on the role of either 
shed or alternatively expressed extracellular domains as poten-
tial functional regulatory mechanisms, either through nega-
tive regulation exerted via loss of functional ligand-binding 
domains and through the inhibitory decoy role of these sol-
uble extracellular regions. However, ectodomain cleavage of 
receptors followed by intracellular juxtamembrane cleavage 
generates intracellular regions which have essential biologi-
cal functions, generation of the Notch receptor cytoplasmic 
domain being one important example. Previous findings 
have revealed an important role for the NRP1 cytoplasmic 
C-terminal PDZ-domain–binding motif in regulating endothe-
lial cell migration and angiogenesis.29,30 The findings presented 
here that NRP1 fragments containing either the cytoplasmic 
or the cytoplasmic, transmembrane and MAM domains but 
lacking the extracellular domain, significantly diminished 
VEGF-induced migration, sprouting angiogenesis in an ex 
vivo model, and VEGFR2 activation, indicate that NRP1 spe-
cies unable to bind VEGF ligands can regulate angiogenic 
signaling. ADAMs processing of NRP1 may function as a 
regulatory feedback mechanism to fine-tune cellular respon-
siveness to ligands for NRP1 or for NRP1 coupled receptors 
such as VEGFR2. Previous work reported that the cytoplasmic 
PDZ-binding domain of NRP1 is essential for NRP1 complex 
formation with VEGFR2.31 Further work will be necessary to 
demonstrate whether NRP1 cytoplasmic domain fragments 
generated by ADAMs-mediated cleavage can regulate func-
tional or pathological angiogenesis in an in vivo setting.
However, the weak association of NRP1 species contain-
ing the cytoplasmic domain but lacking the ligand-binding 
domain with VEGFR2, and the lack of VEGF stimulation 
of association of these species with VEGFR2, indicates that 
the cytoplasmic domain is insufficient for complexation with 
VEGFR2 in the absence of the ligand-binding region. The 
dominant negative effect of cytoplasmic domain species on 
VEGF signaling via VEGFR2 to stimulate cell migration and 
angiogenesis seems therefore to be exerted through an indi-
rect mechanism. The NRP1 cytoplasmic domain associates 
with intracellular signaling molecules such as synectin and 
p130Cas, and these associations may be important for mediat-
ing the role of NRP1 in angiogenesis and cell migration.32,33 
Thus, the inhibitory effect of NRP1 constructs containing the 
cytoplasmic domain and lacking the ligand-binding region 
may be because of binding and sequestration of the NRP1 
cytoplasmic domain to intracellular signaling mediators that 
are essential for normal VEGF angiogenic signaling. These 
findings suggest that the ADAMs-regulated balance between 
full-length NRP1 and cell-associated fragments lacking the 
ligand-binding domain may be important for determining 
angiogenic signaling in response to VEGF.
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Highlights
• NRP1 (neuropilin-1) undergoes cleavage in endothelial cells to generate novel fragments containing the cytoplasmic domain but lacking the 
ligand-binding region.
• These novel species containing the cytoplasmic domain of NRP1 are generated via proteolytic cleavage by ADAMs (a disintegrin and metal-
loproteinases) 9 and 10.
• VEGF (vascular endothelial growth factor) induces formation of novel NRP1 species in endothelial cells containing the cytoplasmic domain via 
ADAMs 9 and 10.
• Overexpression of the novel cytoplasmic fragments of NRP1 in endothelial cells negatively regulates VEGF angiogenic signaling.
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